secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025587
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M
--------------------------------------------------------------------------------

- Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).
- FY24 revenue $693.4M (+30.4%); net loss $705.8M (incl. $547.7M stock comp); Adj. EBITDA loss $104.7M.
- Closed Ambry Genetics acquisition Feb 3, 2025; combined FY25 revenue guidance ~$1.24B (+79% YoY).
- Expects FY25 Adj. EBITDA ~$5M (improvement of ~$110M over FY24).
- CMS reimbursement for Tempus ECG-AF algorithm at $138/test; xT CDx granted ADLT status with $4,500 reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/0000950170-25-025587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000095017025025587/tem-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer